FindTrial
Sign In

Pharmacokinetics and pharmacogenomics study with erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC)

Pharmacokinetics and pharmacogenomics study with erlotinib in the treatment of advanced non-small cell lung cancer (NSCLC) - PK/PG study with erlotinib in NSCLC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006634
Enrollment
40
Registered
2011-11-01
Start date
2011-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

erlotinib

Sponsors

Department of Respiratory Medicine / Keio Cancer Center, School of Medicine, Keio University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Advanced non-small cell lung cancer 2. Treatment with erlotinib is planned 3. Adequate organ functions, PS0-2 4. Written informed concent

Exclusion criteria

Exclusion criteria: Without concent

Design outcomes

Primary

MeasureTime frame
Safety, Efficacy—

Secondary

MeasureTime frame
Pharmacokinetics SNP of drug metabolism related genes—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026